[go: up one dir, main page]

WO2023118005A1 - Composition contenant la combinaison d'un c-glycoside et d'escine pour le soin de la zone de l'œil - Google Patents

Composition contenant la combinaison d'un c-glycoside et d'escine pour le soin de la zone de l'œil Download PDF

Info

Publication number
WO2023118005A1
WO2023118005A1 PCT/EP2022/086794 EP2022086794W WO2023118005A1 WO 2023118005 A1 WO2023118005 A1 WO 2023118005A1 EP 2022086794 W EP2022086794 W EP 2022086794W WO 2023118005 A1 WO2023118005 A1 WO 2023118005A1
Authority
WO
WIPO (PCT)
Prior art keywords
glycoside
weight
escin
composition
propane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2022/086794
Other languages
English (en)
Inventor
Franck JUCHAUX
Carine BALLIHAUT
Julien Laboureau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Publication of WO2023118005A1 publication Critical patent/WO2023118005A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • composition containing the combination of a C-glycoside and escin for the care of the eye area
  • the present invention relates to the cosmetic use of a combination of at least one C-glycoside and escin for the care of the eye contour, particularly redness and/or edema of the periocular region, very particularly bags and/or dark rings in the periocular region.
  • the body in general is sensitive to external aggression from modern life (UV exposure, significant hygrometry and temperature variations, pollution, etc.).
  • the response to this aggression can result inter alia in the onset of redness linked with local vasodilation or in the onset of local edema.
  • the eye contour region due to its structures and its high innervation, represents a particularly sensitive anatomical site to aggression or to behavioral mechanical stress (friction). Its thin skin, depleted of skin lipids, is particularly sensitive to external aggression, exacerbated by loss of firmness and aging.
  • the endothelial cells located on the inner wall of the blood vessels can lose their property of impermeability to the passage of fluids on either side of the capillary walls. These circulation disorders give rise to the onset of eye bags or dark rings.
  • An inflammatory reaction located in this area can also induce a rapid increase in microvascular fluid filtration, giving rise to fluid build-up and ultimately edema of inflammatory origin. This can give rise to pain, in addition to a cosmetic defect.
  • the products currently on the market essentially provide immediate effects and a sensory effect adapted to the eye contour area to treat eye bag, dark ring or edema problems. However, they provide few or no long-lasting effects, in particular on dark rings and/or eye bags associated with inflammatory and/or vascular mechanisms. Moreover, they do not enable simultaneous treatment of the signs of aging of keratin materials such as the skin, which are particularly manifested as a dulling of the skin, visibility of vessels and/or the appearance of wrinkles and lines.
  • This invention helps meet these expectations.
  • the Applicant discovered that the specific combination of a C-glycoside derivative with escin helped strengthen the walls of blood vessels, and treat the signs of aging of keratin materials such as the skin. This helps reduce dark rings, and/or eye bags and/or edema particularly at the eye contour.
  • a C-glycoside derivative formulated with escin in given quantities, has a synergistic or potentiating effect, and makes it possible to limit endothelial tissue permeability, and therefore provide overall care of the eye contour.
  • Such a combination provides overall care of the skin, in particular the eye contour: indeed, it helps reduce dark rings and/or edema and/or signs of skin aging such as wrinkles and lines.
  • Such a combination also enables an optimization of complexion homogeneity, a reduction in relief irregularities and imperfections and a reduction in wrinkles and lines. Finally, such a combination may have a benefit for reducing vascular skin problems on the face or body, which particularly manifest as a dulling of the skin, in particular observed pre- and post-menopause.
  • the invention thus relates to the cosmetic use of a combination of at least one C- glycoside and escin for the care of the eye contour.
  • Care of the eye contour means that the combination according to the invention makes it possible to reduce and/or minimize the appearance of defects around the eyes such as dark rings, eye bags and/or edema and/or makes it possible to reduce the signs of skin aging of the eye contour.
  • such a combination is used to reduce skin relief irregularity, such as for example wrinkles and lines around the eye.
  • such a combination is used to reduce skin coloring defects linked with dark rings, and/or to improve the homogeneity of the complexion and/or skin glow; dark rings fade, and the complexion becomes more homogeneous.
  • Oleder subject means a subject, preferably human, aged at least 60 years, preferably at least 65 years, preferably at least 70 years.
  • the invention also relates to a cosmetic composition, particularly for treating the contour of the eyes, comprising, in a physiologically acceptable medium: from 1% to 10% by weight of active substance with respect to the total weight of the composition of at least one C-glycoside derivative, and, from 0.25 to 10% by weight of active substance with respect to the total weight of the composition of escin.
  • the invention also relates to the cosmetic use of such a composition for the care of the eye contour.
  • the cosmetic composition is used in different types of cosmetic substrates, such as galenic substrates, patches or masks. It can be incorporated into care routines or in treatments accompanying cosmetic procedures. It can also be part of the cosmetic procedure per se.
  • eye contour means an area located around the eye, particularly under the eye and the upper eyelid.
  • radicals optionally being, where applicable, interrupted by 1 , 2, 3 or more heteroatoms chosen from:
  • the bond S-CH2-X represents a C-anomeric type bond, which can be a or p, and the physiologically acceptable salts thereof, the solvates thereof such as hydrates and the isomers thereof.
  • halogen means chlorine, fluorine, bromine or iodine.
  • aryl denotes an aromatic ring system, such as phenyl, optionally substituted by one or more C1 -C4 alkyl radicals.
  • C3 to C8 cycloalkyl denotes an aliphatic ring system having from 3 to 8 carbon atoms, including for example cyclopropyl, cyclopentyl and cyclohexyl.
  • a C-glycoside derivative can comply with formula (I) for which S can represent a monosaccharide or a polysaccharide containing up to 6 sugar units, in pyranose and/or furanose form and L and/or D series, said mono- or polysaccharide having at least one mandatorily free hydroxyl function and/or optionally one or more mandatorily protected amine functions, X and R also retaining all of the definitions given above.
  • S can represent a monosaccharide or a polysaccharide containing up to 6 sugar units, in pyranose and/or furanose form and L and/or D series, said mono- or polysaccharide having at least one mandatorily free hydroxyl function and/or optionally one or more mandatorily protected amine functions, X and R also retaining all of the definitions given above.
  • a monosaccharide according to the invention can be chosen from D-glucose, D-galactose, D-mannose, D-xylose, D-lyxose, L-fucose, L-arabinose, L- rhamnose, D-glucuronic acid, D-galacturonic acid, D-iduronic acid, N-acetyl-D- glucosamine, N-acetyl-D-galactosamine and advantageously denotes D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose, and in particular D-xylose.
  • a polysaccharide according to the invention containing up to 6 sugar units can be chosen from D-maltose, D-lactose, D-cellobiose, D-maltotriose, a disaccharide associating a uronic acid chosen from D-iduronic acid or D-glucuronic acid with a hexosamine chosen from D-galactosamine, D-glucosamine, N-acetyl-D- galactosamine, N-acetyl-D-glucosamine, an oligosaccharide containing at least one xylose which can be advantageously chosen from xylobiose, methyl-p-xylobioside, xylotriose, xylotetraose, xylopentaose and xylohexaose and particularly xylobiose which is composed of two xylose molecules bound by a 1 -4 bond.
  • S can represent a monosaccharide chosen from D-glucose, D- xylose, L-fucose, D-galactose, D-maltose and particularly D-xylose.
  • a C-glycoside derivative complying with formula (I) can be used, for which R represents a saturated C1 to C20, in particular C1 to C10, or unsaturated C2 to C20, in particular C3 to C10, linear alkyl radical, or a saturated or unsaturated, C3 to C20 branched or cyclic alkyl radical; in particular C4 to C10, and optionally substituted as described above, S and X also retaining all of the definitions given above.
  • R can denote a C1 -C4, particularly C1 -C2, linear radical, optionally substituted by -OH, -COOH or -COOR”2, R”2 being a saturated C1-C4 linear alkyl radical, particularly methyl.
  • R can denote a non-substituted C1 -C4, particularly C1 -C2, linear alkyl radical, in particular methyl.
  • - R represents a saturated C1 to C20, in particular C1 to C10, or unsaturated C2 to C20, in particular C3 to C10, linear alkyl radical, or a saturated or unsaturated, C3 to C20, in particular C4 to C10, branched or cyclic alkyl radical and optionally substituted as described above;
  • - S represents a monosaccharide as described above, preferably D-glucose, D- xylose, N-acetyl-D-glucosamine or L-fucose, and in particular D-xylose;
  • - X represents a radical chosen from -CO-, -CH(OH)-, -CH(NH 2 )-, and preferably a -CH(OH)- group.
  • R denotes a C1 -C4, particularly C1 -C3, linear radical, optionally substituted by - OH, -COOH or -COOR”2, R”2 being a saturated C1-C4 linear alkyl radical, particularly methyl;
  • - S represents a monosaccharide as described above, preferably D-glucose, D- xylose, N-acetyl-D-glucosamine or L-fucose, and in particular D-xylose;
  • - X represents a radical chosen from -CO-, -CH(OH)-, -CH(NH 2 )-, and preferably a -CH(OH)- group.
  • a C-glycoside derivative of formula (I) can be used, for which: - R denotes a non-substituted C1 -C4, particularly C1 -C2, linear alkyl radical, in particular methyl;
  • - S represents a monosaccharide as described above, preferably D-glucose, D- xylose, N-acetyl-D-glucosamine or L-fucose, and in particular D-xylose;
  • - X represents a group chosen from -CO-, -CH(OH)-, -CH(NH2)-, and preferably a - CH(OH)- group.
  • the acceptable salts for the non-therapeutic use of the compounds described in the present invention comprise conventional non-toxic salts of said compounds such as those formed from organic or inorganic acids.
  • the salts of mineral acids such as sulfuric acid, hydrochloric acid, hydrobromic acids, hydroiodic acid, phosphoric acid, boric acid.
  • organic acid salts can include one or more carboxylic, sulfonic or phosphonic acid group(s). They can consist of linear, branched or cyclic aliphatic acids or indeed aromatic acids. These acids can further include one or more heteroatoms selected from O and N, for example in the form of hydroxyl groups. Mention can particularly be made of propionic acid, acetic acid, terephthalic acid, citric acid, and tartaric acid.
  • the acid group(s) can be neutralized with a mineral base, such as LiOH, NaOH, KOH, Ca(OH)2, NH4OH, Mg(OH)2 or Zn(OH)2; or by an organic base such as a primary, secondary or tertiary alkylamine, for example triethylamine or butylamine.
  • a mineral base such as LiOH, NaOH, KOH, Ca(OH)2, NH4OH, Mg(OH)2 or Zn(OH)2
  • an organic base such as a primary, secondary or tertiary alkylamine, for example triethylamine or butylamine.
  • This primary, secondary or tertiary alkylamine can include one or more nitrogen and/or oxygen atoms and can therefore include for example one or more alcohol functions; mention can particularly be made of amino-2-methyl-2- propanol, triethanolamine, dimethylamino-2-propanol, 2-amino-2-(hydroxymethyl)-1 ,3- propanediol. Mention can further be made of lysine or 3-(dimethylamino)propylamine.
  • the acceptable solvates for the compounds described in the present invention comprise conventional solvates such as those formed during the final preparation step of said compounds due to the presence of solvents.
  • solvates due to the presence of water or linear or branched alcohols such as ethanol or isopropanol.
  • C-beta-D-xylopyranoside-2-hydroxy-propane Preferably, C-beta-D-xylopyranoside-2-hydroxy-propane or
  • C-alpha-D-xylopyranoside-2-hydroxy-propane is used, and more preferably C-beta-D-xylopyranoside-2-hydroxy-propane.
  • a C-glycoside of formula (I) suitable for the invention can be advantageously C-beta-D-xylopyranoside-2-hydroxy- propane, of which the INCI name is HYDROXYPROPYL TETRAHYDROPYRANTRIOL particularly sold under the name MEXORYL SBB® or MEXORYL SCN® by NOVEAL.
  • MEXORYL SBB® for example contains 35% by weight of hydroxypropyl tetrahydropyrantriol in 40% by weight water and 25% propylene glycol.
  • composition according to the invention comprises at least one C-glycoside derivative at a content of 1% to 10% by weight of active substance with respect to the total weight of the composition, and preferably from 2% to 9% by weight of active substance, and more specifically from 3% to 7% by weight of active substance.
  • a C-glycoside as defined above is used in combination with escin. Such a combination proves to be particularly advantageous in terms of effectiveness, particularly for overall cosmetic care of the eye contour.
  • composition according to the invention comprises escin.
  • the escin can be of synthetic or natural origin.
  • Synthetic origin means escin, in the pure state or in solution regardless of the concentration thereof in said solution, obtained by chemical synthesis.
  • Natural origin means escin, in the pure state or in solution regardless of the concentration thereof in said solution, obtained from a natural element and/or comprised therein such as for example a plant extract, particularly a horse chestnut extract.
  • the escin according to the invention is marketed by Indena under the trade name 3030000 ESCIN FREE ACID®.
  • composition according to the invention also comprises a physiologically acceptable medium.
  • This physiologically acceptable medium can be chosen by a person skilled in the art based on their general knowledge according to the type of composition sought.
  • said physiologically acceptable medium comprises an aqueous phase and/or a fatty phase.
  • a composition considered in the invention can be formulated in the form of a solid, semi-solid, or liquid emulsion.
  • the composition according to the invention is an aqueous composition.
  • aqueous composition means any composition comprising at least 5% by weight of water with respect to the total weight of the composition and preferably from 5 to 99% by weight and even more preferably from 20 to 99% by weight.
  • the composition according to the invention is anhydrous.
  • “Anhydrous composition” means any composition comprising less than 5% by weight of water with respect to the total weight of the composition and more preferably less than 1 % water, preferably less than 0.5% by weight of water, preferably any composition free from water.
  • a composition according to the invention can be administered topically.
  • the composition can take the form in particular of an aqueous or oily solution; of a dispersion of the lotion or serum type; of an emulsion of liquid or semi-liquid consistency of the milk type obtained by dispersing a fatty phase in an aqueous phase (O/W), conversely (W/O), or triple O/W/O or W/O/W; of a suspension or emulsion of soft consistency of the cream or aqueous or anhydrous gel type; of microcapsules or microparticles; of ionic and/or non-ionic type vesicular dispersions.
  • composition comprises an aqueous phase
  • it comprises water, a floral water and/or a mineral water.
  • Said aqueous phase can further comprise one or more organic solvents such as a C1 -C8 alcohol, particularly ethanol, isopropanol, tert-butanol, n-butanol, pentanol, hexanol, polyols such as glycerin, propylene glycol, butylene glycol, capryl/caprylic glycol, isoprene glycol, polyethylene glycol and polyol ethers.
  • organic solvents such as a C1 -C8 alcohol, particularly ethanol, isopropanol, tert-butanol, n-butanol, pentanol, hexanol, polyols such as glycerin, propylene glycol, butylene glycol, capryl/caprylic glycol, isoprene glycol, polyethylene glycol and polyol ethers.
  • composition according to the invention when the composition according to the invention is in the form of an emulsion, it can optionally further comprise a surfactant, preferably at a quantity of 0.01 to 30% by weight with respect to the total weight of the composition.
  • the composition according to the invention can also comprise at least one co-emulsifier which can be chosen from oxyethylenated sorbitan monostearate, fatty alcohols such as stearyl alcohol or cetyl alcohol, or esters of fatty acids and polyols such as glyceryl stearate.
  • composition according to the invention can also comprise a fatty phase, particularly consisting of fats that are liquid at 25°C, such as oils of animal, plant, mineral or synthetic origin, optionally volatile; fats that are solid at 25°C such as waxes of animal, plant, mineral or synthetic origin; pasty fats; gums; mixtures thereof.
  • Volatile oils are generally oils having, at 25°C, a saturation vapor pressure at least equal to 0.5 millibar (or 50 Pa).
  • hydrocarbon oils such as isoparaffins and particularly isododecane and fluorinated oils
  • C1 -C20 siloxanes and particularly those with trimethylsilyl terminal groups, of which mention can be made of linear polydimethylsiloxanes and alkylmethylpolysiloxanes such as cetyldimethicone (CTFA name),
  • waxes of animal, plant, mineral or synthetic origin such as microcrystalline waxes, paraffin, petrolatum, petroleum jelly, ozokerite, montan wax; beeswax, lanolin and derivatives thereof; Candelilla, Ouricury, Carnauba, Japan wax, cocoa butter, cork fiber or sugar cane waxes; hydrogenated oils that are solid at 25°C, ozokerites, fatty esters and glycerides that are solid at 25°C; polyethylene, polymethylene waxes and waxes obtained by Fischer-Tropsch synthesis; hydrogenated oils that are solid at 25°C; lanolins; fatty acid esters that are solid at 25°C; silicone waxes; fluorinated waxes.
  • composition according to the invention can also comprise usual adjuvants in the field in question, such as hydrophilic of lipophilic gelling agents, hydrophilic or lipophilic, particularly cosmetic or pharmaceutical, active agents, preservatives, antioxidants, perfumes, fillers, thickening polymers, sequestering agents, pigments, nacres, UV filters, odor absorbers and dyes.
  • adjuvants depending on their nature, can be introduced in the fatty phase, in the aqueous phase and/or in lipid spherules.
  • compositions according to the invention can particularly be in the form of a composition intended for the care and/or treatment of dark rings, bags and/or edema in the periocular region.
  • compositions according to the invention are particularly in the form of:
  • a product for the care, treatment, cleansing or protection of the skin of the face or body such as a (day, night, moisturizing) care composition for the face or body; an antiwrinkle or anti-aging composition for the face; a mattifying composition for the face; a composition for irritated skins; a makeup removal composition; a particularly moisturizing optionally after-sun milk for the body;
  • a makeup product for the skin of the face, body or lips such as a foundation, a tinted cream, a blusher or eye shadow, a free or compact powder, an anti-dark ring stick, a concealer stick, a lipstick, a lip care product.
  • compositions according to the invention find a preferred application as a facial skin care composition, of the anti-dark ring or anti-aging type.
  • composition used according to the invention can furthermore contain other active agents, and particularly at least one compound chosen from: moisturizing agents; anti-glycation agents; NO-synthase inhibitors; agents stimulating dermal or epidermal macromolecule synthesis and/or preventing the degradation thereof and/or involved in the organization thereof; agents stimulating fibroblast and/or keratinocyte proliferation or stimulating keratinocyte differentiation; agents involved in the energy metabolism; sun filters, and mixtures thereof.
  • “Moisturizing agent” means:
  • ceramides sphingoid-based compounds, lecithins, glycosphingolipids, phospholipids, cholesterol and derivatives thereof, phytosterols (stigmasterol, p-sitosterol, campesterol), essential fatty acids, 1 -2 diacylglycerol, 4-chromanone, pentacyclic triterpenes such as ursolic acid, petroleum jelly and lanolin;
  • a compound directly increasing the water content of the stratum corneum such as trehalose and derivatives thereof, hyaluronic acid and derivatives thereof, glycerol, pentanediol, sodium pidolate, serine, xylitol, sodium lactate, glycerol polyacrylate, ectoin and derivatives thereof, chitosan, oligo- and polysaccharides, cyclic carbonates, N-lauroyl pyrrolidone carboxylic acid, and N-a-benzoyl-L-arginine; film-forming polymers,
  • a compound activating the sebaceous glands such as DHEA, the oxidized and/or 17-alkylated derivatives thereof, sapogenins and vitamin D and derivatives thereof.
  • Anti-glycation agent means a compound preventing and/or reducing glycation of skin proteins, in particular proteins of the dermis such as collagen.
  • antiglycation agents are plant extracts from the Ericaceae family, such as a blueberry extract (Vaccinium angustifolium); ergothioneine and derivatives thereof; and hydroxystilbenes and derivatives thereof, such as resveratrol and 3,3',5,5'-tetrahydroxystilbene.
  • NO-synthase inhibitors suitable for use in the present invention particularly comprise a Vitis vinifera species plant extract which is particularly marketed by EUROMED under the name LEUCOCYANIDINES® grape seed extract, or by INDENA under the name LEUCOSELECT®, or finally by HANSEN under the name EXTRAIT DE MARC DE RAISIN; an Olea europaea species plant extract which is preferably obtained from olive leaves and is particularly marketed by VINYALS in dry extract form, or by BIOLOGIA & TECHNOLOGIA under the trade name EUROL BT; and a Gingko biloba species plant extract which is preferably a dry aqueous extract of this plant sold by BEAUFOUR under the trade name GINKGO BILOBA EXTRAIT STANDARD.
  • a Vitis vinifera species plant extract which is particularly marketed by EUROMED under the name LEUCOCYANIDINES® grape seed extract, or by INDENA under the name LEUCOSELECT®, or finally by
  • active agents stimulating dermal macromolecules or preventing the degradation thereof mention can be made of those acting: - either on collagen synthesis, such as Centella asiatica extracts; asiaticosides and derivatives; synthetic peptides such as iamin, biopeptide CL or palmitoyloligopeptide marketed by SEDERMA; peptides extracted from plants, such as soy hydrolysate marketed by COLETICA under the trade name PHYTOKINE®; and plant hormones such as auxins and lignans.
  • elastin synthesis such as Saccharomyces Cerivisiae extract marketed by BASF under the trade name CYTOVITIN®; and Macrocystis pyrifera algae extract marketed by SECMA under the trade name KELPADELIE®;
  • MMP metaloproteinase
  • ADAM protein A Disintegrin And Metalloprotease
  • serine proteases such as leukocyte elastase or cathepsin G.
  • the agents stimulating keratinocyte proliferation suitable for use in the composition according to the invention, particularly comprise retinoids such as retinol and esters thereof, of which retinyl palmitate; phloroglucinol; walnut meal extracts marketed by GATTEFOSSE; and Solanum tuberosum extracts marketed by SEDERMA.
  • retinoids such as retinol and esters thereof, of which retinyl palmitate; phloroglucinol; walnut meal extracts marketed by GATTEFOSSE; and Solanum tuberosum extracts marketed by SEDERMA.
  • the agents stimulating keratinocyte differentiation comprise for example minerals such as calcium; lupine extract marketed by SILAB under the trade name Photopreventine®; sodium beta-sitosteryl sulfate marketed by SEPORGA under the trade name PHYTOCOHESINE®; and corn extract marketed by SOLABIA under the trade name PHYTOVITYL®; and lignans such as secoisolariciresinoL
  • creatine-creatinine such as Tego Cosmo C 100 from Degussa, EUGLENA GRACILIS or Chronodyn extract from Sederma.
  • Filling agents such as for example hyaluronic acid, lipids, dermal relaxing agents such as for example adenosine, Boswellic acid, aniseed extract particularly BIOXILIFT from Silab, dermal contracting agents such as for example DMAE (dimethylaminoethanol), THPED (N,N,N’,N’-tetrakis(2-hydroxypropyl)-ethylenediamine).
  • the C-glycoside used is C-beta-D-xylopyranoside- 2-hydroxy-propane (INCI name: hydroxypropyl tetrahydropyrantriol).
  • Endothelial cells from dermal microvessels were seeded in culture inserts pretreated with fibronectin, then the inserts were placed in 24-well culture plates. The cells were cultured for 7 days in culture medium (EGM-2 medium supplemented with 5% fetal calf serum (FCS)) with renewal of the culture medium after 1 and 4 days of culture.
  • EMM-2 medium supplemented with 5% fetal calf serum (FCS)
  • test medium EMM-2 medium supplemented with 0.2% bovine serum albumin (BSA)
  • BSA bovine serum albumin
  • C-Glycoside tested at 1 and 3 mM
  • diosmin tested at 1 and 3 pM
  • escin tested at 1 and 3 pM
  • C-Glycoside + Escin (1 mM C-Glycoside + 1 pM Escin; 3 mM C-Glycoside + 3 pM Escin
  • C-Glycoside + Diosmin 1 mM C-Glycoside + 1 pM Diosmin; 3 mM C- Glycoside + 3 pM Diosmin.
  • the fluorescent tracer (FITC-Dextran) was added to the inserts (upper compartment) and the cultures were incubated for 1 hour.
  • the medium of the lower compartment was transferred to a 96-well plate and a fluorescence measurement was made ( ex c 485 nm, Z, emm 535 nm) using a spectrofluorometer. A protection percentage was calculated accounting for the fluorescence measured under unstimulated control conditions and accounting for the fluorescence measured under the control conditions after inducing inflammation with TNF-a according to the formula:
  • TNF-a treatment substantially increases the vascular permeability displayed by an increase in the diffusion of the fluorescent tracer (FITC- Dextran).
  • FITC- Dextran fluorescent tracer
  • Dexamethasone tested at 1 pM used as the pharmacological reference molecule, protected the cells significantly from the effects of TNF-a (57% protection, p ⁇ 0.001, Table 1 ).
  • the effect of TNF-a on vascular permeability and the effect of Dexamethasone on vessel wall strengthening were expected and make it possible to validate the test.
  • Endothelial cells from umbilical veins were seeded in 96-well culture plates and incubated for 24 hours in culture medium (EGM-2 medium supplemented with 5% fetal calf serum (FCS)). The culture medium was then renewed with culture medium containing or not (Control), 1 pM of IKK Inhibitor X (Pharmacological reference, compound having the CAS number 431898-65-6), or C-Glycoside (tested at 1 and 3 mM), or diosmin (tested at 1 or 3 pM), or escin (tested at 1 and 3 pM), or the combination of C-Glycoside + Escin (1 mM C-Glycoside + 1 pM Escin; 3 mM C-Glycoside + 3 pM Escin), or the combination of C- Glycoside + Diosmin (1 mM C-Glycoside + 1 pM Diosmin; 3 mM C-Glycoside + 3
  • the culture media were collected and the quantity of IL-8 was quantified using an ELISA kit according to the supplier's recommendations. A protection percentage was calculated accounting for the quantity of IL-8 measured under unstimulated control conditions and accounting for the quantity of IL-8 measured under the control conditions after inducing inflammation with TNF-a according to the formula:
  • TNF-a treatment substantially increases IL-8 secretion by endothelial cells thus expressing the onset of inflammation.
  • IKK Inhibitor X tested at 10 pM, used as the pharmacological reference molecule protected the cells significantly from inflammation induced by TNF-a (97% protection, p ⁇ 0.001).
  • the effect of TNF-a on inflammation and the anti-inflammatory effect of IKK Inhibitor X were expected and make it possible to validate the test.
  • C-Glycoside tested at 1 and 3 mM, diosmin tested at 1 and 3 pM did not exhibit an anti-inflammatory effect unlike Escin tested at 3 pM which protected the endothelial cells by 24% (p ⁇ 0.01) from inflammation induced by TNF-a.
  • the 3 mM C-Glycoside + 3 pM Escin combination exhibited a clear protective effect greater than that observed with Escin alone (respectively 32% and 24% protection, p ⁇ 0.01).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne l'utilisation cosmétique d'une combinaison d'au moins un C-glycoside et d'escine pour le soin du contour de l'œil. L'invention concerne également une composition cosmétique, en particulier pour le traitement du contour des yeux, comprenant, dans un milieu physiologiquement acceptable : de 1 % à 10 % en poids de substance active par rapport au poids total de la composition d'au moins un dérivé de C-glycoside, et de 0,25 à 10 % en poids de principe actif par rapport au poids total de la composition d'escine.
PCT/EP2022/086794 2021-12-20 2022-12-19 Composition contenant la combinaison d'un c-glycoside et d'escine pour le soin de la zone de l'œil Ceased WO2023118005A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FRFR2113976 2021-12-20
FR2113976A FR3130602A1 (fr) 2021-12-20 2021-12-20 Composition contenant l'association d'un C-glycoside et de l'escine pour le soin du contour des yeux

Publications (1)

Publication Number Publication Date
WO2023118005A1 true WO2023118005A1 (fr) 2023-06-29

Family

ID=80735768

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/086794 Ceased WO2023118005A1 (fr) 2021-12-20 2022-12-19 Composition contenant la combinaison d'un c-glycoside et d'escine pour le soin de la zone de l'œil

Country Status (2)

Country Link
FR (1) FR3130602A1 (fr)
WO (1) WO2023118005A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926021A1 (fr) * 2008-01-03 2009-07-10 Oreal Utilisation de derives c-glycoside a titre d'actif vasculaire
CN113262192A (zh) * 2020-02-17 2021-08-17 玫琳凯有限公司 局部用化妆品组合物
CN113797136A (zh) * 2021-10-27 2021-12-17 北京旋光普利生物医药科技开发有限公司 一种抗皱淡纹眼霜膏乳液的组合制备

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926021A1 (fr) * 2008-01-03 2009-07-10 Oreal Utilisation de derives c-glycoside a titre d'actif vasculaire
CN113262192A (zh) * 2020-02-17 2021-08-17 玫琳凯有限公司 局部用化妆品组合物
CN113797136A (zh) * 2021-10-27 2021-12-17 北京旋光普利生物医药科技开发有限公司 一种抗皱淡纹眼霜膏乳液的组合制备

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAS, no. 431898-65-6
DATABASE GNPD [online] MINTEL; 2 November 2021 (2021-11-02), ANONYMOUS: "Anti-Ageing Eye Contour Care", XP055951854, retrieved from https://www.gnpd.com/sinatra/recordpage/9034064/ Database accession no. 9034064 *
DATABASE GNPD [online] MINTEL; 28 August 2009 (2009-08-28), ANONYMOUS: "Anti-Wrinkle Micro-Lifting Serum", XP055951977, retrieved from https://www.gnpd.com/sinatra/recordpage/1166841/ Database accession no. 1166841 *

Also Published As

Publication number Publication date
FR3130602A1 (fr) 2023-06-23

Similar Documents

Publication Publication Date Title
ES2640042T3 (es) Composición, particularmente cosmética, que comprende ácido ascórbico en asociación con un derivado de ácido ascórbico
ES2701598T3 (es) Utilización de sustancias activas naturales en composiciones cosméticas o terapéuticas
ES2223862T3 (es) Nuevos compuestos de la familia de las n-acilaminoamidas, composiciones que las comprenden y utilizaciones.
WO2020024703A1 (fr) Composition topique de fullerène soluble dans l'eau
KR102625374B1 (ko) 피부 및/또는 점막을 수화시키기 위한 네펠리움 라파세움의 과피의 추출물의 용도
US11285093B2 (en) Cosmetic uses of swertiamarin
KR20100136537A (ko) 미생물 매트로부터 유래된 엑소폴리사카라이드를 포함하는 화장료 조성물 및 그것의 용도
ES2697773T3 (es) Uso cosmético y/o dermatológico de un extracto de hojas de Hamamelis virginiana
JP2022511023A (ja) シスツス・モンスペリエンシス（Ｃｉｓｔｕｓ ｍｏｎｓｐｅｌｉｅｎｓｉｓ）の抽出物の新規な化粧品的及び皮膚科学的使用
US11090205B2 (en) Methods and compositions for treatment of skin conditions
ES2626266T3 (es) Uso en cosmética de un derivado C-glicósido en asociación con ácido ascórbico
JP2016510016A (ja) 褐藻抽出物、酵母抽出物及びアスコルビン酸を含有する化粧品組成物
EP1889642A2 (fr) Compositions cosmétiques associant un dérivé C-glycoside et un dérivé N-acylaminoamide
ES2351992T3 (es) Composición cosmética o dermatológica que comprende unos derivados de acilaminoamida.
KR101502475B1 (ko) 오돈텔라 아우리타의 친지성 추출물의 피부 재구조화를위한 용도, 사용되는 조성물 및 상기 추출물을 사용하는화장 방법
FR2926021A1 (fr) Utilisation de derives c-glycoside a titre d'actif vasculaire
KR20110050450A (ko) 키토산 및 디카르복실산을 포함하는 주사 질환의 치료용 조성물
WO2023118005A1 (fr) Composition contenant la combinaison d'un c-glycoside et d'escine pour le soin de la zone de l'œil
CN109937029A (zh) 抗老化迹象的组合和方法
BRPI0713959A2 (pt) composiÇço cosmÉtica e/ou dermatolàgica tàpica, conjunto cosmÉtico, utilizaÇço cosmÉtica de uma composiÇço, processo de tratamento cosmÉtico, e, utilizaÇço de pelo menos um Ácido hialurânico ou um de seus derivados e de pelo menos um derivado c-glicosÍdeo
CN113181070A (zh) 一种具有祛皱抗衰作用的润肤霜及其制备方法
KR102856466B1 (ko) 세라마이드 및 스핑고지질을 포함하는 화장료 조성물
US20240225986A9 (en) Compositions and methods for improving the appearance of the skin
KR20240068867A (ko) 포피라334가 봉입된 세포외소포체의 용도
FR2894144A1 (fr) Utilisation du dipeptide tyrosine-arginine dans une composition cosmetique ou pour la preparation d'un medicament

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22840640

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22840640

Country of ref document: EP

Kind code of ref document: A1